HIV/AIDS Clinical Trials Unit (CTU) COVID-19 Admin Supplement

Project Summary/Abstract: The University of North Carolina (UNC) Global HIV Clinical Trials Unit (CTU) has a wellestablished track record of high-quality, innovative clinical research, strong scientific leadership(both in and outside the NIH HIV/AIDS Networks), and access to critically important infected andat-risk populations in the Southeastern US, Southeast Asia and in Southern Africa. Drawn froma diverse team of clinical innvestigators spanning two continents, our is led by experiencedprincipal investigators (Joseph Eron MD and Mina Hosseinipour MD) and will support all 5 NIHHIV Clinical Trials Networks: Adult Therapeutic Strategies, Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations, Integrated HIV PreventionStrategies, Microbicide Strategies, and Vaccine Strategies to Prevent HIV Infection. The ClinicalResearch Sites (CRS) include Chapel Hill CRS led by David Wohl MD (Adult TherapeuticStrategies, Integrated Prevention, Microbicide and Vaccine), Greensboro CRS led by CorneliusVan Dam MD PhD (Adult Therapeutic Strategy and Integrated Prevention), Malawi CRS led byLameck Chinula MD (all 5 Networks) and Vietnam (protocol specific site) led by Vivian Go.Supporting this leadership is a well-organized research team, comprising global experts and sitecollaborators who will work to execute the network scientific agendas. The CTU has alsoassembled a diverse group of senior scientists and public health officials to serve on ourScientific and Strategic Advisory Group. The CTU administration incorporates a highlyorganized structure that will be responsive to our experienced research teams across the CRSand will provide ongoing evaluation to ensure optimal performance and efficiency. The CTU issupported by state-of-the-art communications and outstanding laboratory, pharmacy, qualityassurance, data management and regulatory support. With its robust administrative framework,the UNC Global HIV CTU is optimally positioned to provide scientific leadership and clinicaltrials infrastructure to advance the field of agenda of the NIAID HIV networks and emerginginfectious disease such as the SARS-CoV-2 pandemic.